Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Gastroenterology

Journal Scan / Research · December 20, 2022

Vonoprazan–Amoxicillin Dual Therapy as First-Line Treatment of Helicobacter pylori Infection

The American Journal of Gastroenterology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The American Journal of Gastroenterology
Ten-Day Vonoprazan-Amoxicillin Dual Therapy as a First-Line Treatment of Helicobacter pylori Infection Compared With Bismuth-Containing Quadruple Therapy
Am. J. Gastroenterol 2022 Dec 02;[EPub Ahead of Print], HS Qian, WJ Li, YN Dang, et al

Further Reading